Down syndrome (Trisomy 21): There are 400,000 people in the U.S. living with Trisomy 21 (Down syndrome). Meiogen holds issued and pending methods patents for the treatment of neurological diseases, including Down syndrome (US Patent #5,780,027), using interferon inhibition. In Down syndrome, an over-abundance of interferon- α and interferon- γ receptors encoded on an extra 21st chromosome leads to excessive interferon activity. Meiogen’s trisomy mouse model studies documented dramatically improved development ¹ and cultured neuron viability ² using anti-interferon antibodies. These observations were subsequently confirmed using interferon receptor gene mutations to reduce the bioactivity of both interferon types ³ .